Health Care & Life Sciences » Biotechnology | Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG | Cash Flow

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
5,760.00
7,950.00
2,934.00
33,194.00
51,275.00
53,864
Depreciation, Depletion & Amortization
53.00
75.00
1,122.00
3,264.00
3,382.00
3,741
Other Funds
787.00
1,178.00
24,327.00
4,924.00
7,945.00
6,299
Funds from Operations
6,494.00
6,697.00
23,332.00
25,006.00
39,948.00
43,824
Changes in Working Capital
482.00
634.00
942.00
2,131.00
315.00
5,959
Net Operating Cash Flow
6,976.00
6,063.00
22,390.00
27,137.00
39,633.00
37,865
Capital Expenditures
4.00
207.00
515.00
375.00
1,397.00
Purchase/Sale of Investments
276.00
-
104.00
84.00
20,842.00
Net Investing Cash Flow
272.00
207.00
619.00
459.00
22,239.00
Issuance/Reduction of Debt, Net
909.00
-
-
-
-
Net Financing Cash Flow
531.00
18,661.00
82,630.00
631.00
57,108.00
Net Change in Cash
7,239.00
12,391.00
59,424.00
27,044.00
4,620.00
Free Cash Flow
6,980.00
6,223.00
22,740.00
27,426.00
40,894.00
Deferred Taxes & Investment Tax Credit
-
-
3,061.00
-
-
-
Change in Capital Stock
378.00
18,661.00
82,630.00
631.00
161.00
Exchange Rate Effect
4.00
-
197.00
79.00
144.00

About Santhera Pharmaceuticals Holding

View Profile
Address
Hohenrainstrasse 24
Pratteln Basel-Landschaft (Basle Country) 4133
Switzerland
Employees -
Website http://www.santhera.com
Updated 07/08/2019
Santhera Pharmaceuticals Holding AG is a pharmaceutical company. It engages in the development, marketing, and commercialization of pharmaceutical products for the treatment of neuro-ophthalmological, neuromuscular, and pulmonary diseases. It offers its products under the Raxone brands.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.